Anna Stefos

I bring a bidirectional governance lens that is rare at the board table: fluency in both industrial operations and mission-critical healthcare systems, built across GM, Stellantis, and federal healthcare. That combination is most valuable to boards navigating complexity or transformation, where the need is a director who can see risk before it surfaces and ask the questions management hasn%27t had to answer yet.

Companies that would benefit the most from my unique perspective: PE-backed mid-cap companies in healthcare and industrial sectors navigating transformation, complex risk, or a consequential strategic inflection point, where the board needs judgment that spans both operations and mission-critical systems.